GQG Partners’s Royalty Pharma RPRX Stock Holding History

GQG Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,902	Closed	-$345K	–	88
2021 Q1	$345K	Sell	7,902 -813,553	-99%	-$38.6M	﹤0.01%	61
2020 Q4	$41.1M	Buy	+821,455	New	+$34.9M	0.14%	48

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

GQG Partners's RPRX Position: Q2 2021 in Review

GQG Partners sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 7,902 shares — an estimated $345K sold.

GQG Partners first reported a position in RPRX in Q4 2020 and held it in 2 quarters. The position peaked at $41.1M in Q4 2020. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

GQG Partners reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
GQG Partners sold 7,902 Royalty Pharma shares in Q2 2021, an estimated $345K.
GQG Partners first reported a position in Royalty Pharma in Q4 2020 and held it in 2 quarters.
GQG Partners's Royalty Pharma position peaked at $41.1M in Q4 2020.
236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on GQG Partners's 13F filing for Q2 2021, filed 13 Aug 2021.